Ozempic and Wegovy: what is the difference between them?

Do Ozempic and Wegovy contain the same thing?

Yes, and that is precisely where the confusion starts. Both contain semaglutide, a GLP-1 receptor agonist that slows gastric emptying, reduces appetite and influences blood-sugar regulation. The chemistry is identical. What differs is the approved dose, the clinical population the medicine was studied in for each indication, and (critically) the legal licence.

The MHRA licences medicines for specific uses based on the evidence submitted. Ozempic was approved for adults with type 2 diabetes; its maintenance doses are 0.5mg and 1mg weekly (with 2mg for some patients). Wegovy was developed specifically for weight management, with a higher maintenance dose of 2.4mg weekly (rising to 7.2mg following the MHRA's April 2026 approval of the dedicated single-dose pen) reached through a gradual titration. The higher dose range reflects the evidence gathered in weight-management trials, the STEP 1 trial published in the New England Journal of Medicine studied 2.4mg specifically in adults with obesity and found an average weight reduction of around 15% over 68 weeks. You can read the full picture on our Wegovy overview page.

Using Ozempic off-label for weight loss bypasses the evidence base on which the weight-management licence is built. That is not a technicality; it is a clinically meaningful distinction.

Are the side effects and safety profiles different between Ozempic and Wegovy?

Because both medicines contain semaglutide, their side-effect profiles are broadly similar: nausea, diarrhoea, constipation, indigestion, burping and fatigue are the most common, typically peaking after a dose increase and easing within days to a couple of weeks. The higher doses used in Wegovy's weight-management schedule do carry a higher incidence of gastrointestinal effects compared with the lower doses used in Ozempic for diabetes.

The NHS patient information for semaglutide covers both products' known effects; the NHS semaglutide medicines page is a reliable starting point. Both carry a Black Triangle (▼) designation, meaning they are under additional MHRA monitoring. Pancreatitis is a known but infrequent serious risk for GLP-1 medicines; the MHRA has specifically highlighted severe, persistent stomach pain that may radiate to the back as a sign requiring urgent medical attention.

One practical note: if you keep Wegovy at home, the pen lives in the fridge at 2–8°C. Always check the Patient Information Leaflet for the precise window if you need to take it out temporarily. A missed-dose question or a concern about a side effect belongs with your prescriber, not a search engine.

Who can legally be prescribed each one in the UK, and where does that leave weight-loss patients?

Ozempic is approved for adults with type 2 diabetes. Prescribing it for weight loss in the absence of a diabetes diagnosis would be an off-label use, which falls outside the licensed indication. The NHS England guidance on weight-management injections is clear that Wegovy, not Ozempic, is the semaglutide medicine indicated for obesity treatment.

Wegovy's eligibility threshold is adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition, for example, high blood pressure, raised cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under NICE guidance. NICE's appraisal of semaglutide for weight management (TA875) recommends it within specialist services for a maximum of two years; private prescribing operates within the licensed indication but is not subject to the same specialist-service requirement.

For anyone wondering about the broader landscape of semaglutide options, there is also an oral version: the Wegovy tablet was approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management. It uses the same active ingredient, without injections. If you want to understand what the differences between Ozempic and Wegovy mean for your treatment choices, a dedicated page covers this in detail.

What are the weight-loss medicine options actually licensed in the UK?

Two injectable GLP-1-based medicines currently hold UK licences for weight management: Wegovy (semaglutide) and Mounjaro (tirzepatide). Mounjaro is a dual GIP and GLP-1 receptor agonist, the only one of its kind licensed here. In the SURMOUNT-5 trial (published in the New England Journal of Medicine in 2025), tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in a head-to-head comparison. That does not make it universally the better choice; which is appropriate depends on your medical history, other medicines you take, and how your body responds.

Ozempic is not on that list. Neither is Rybelsus, which is also oral semaglutide but licensed only for type 2 diabetes. If you are researching your options, the weight-loss treatment overview sets out what is available. Our clinical team page (starting with our lead prescriber) gives you a sense of who is reviewing these decisions.

A comparison of the cost picture for Wegovy specifically is on our Wegovy price page, and if you are still weighing up the difference between Wegovy and Ozempic, that page covers the head-to-head in more detail alongside our guide to what sets Ozempic and Wegovy apart and a closer look at the practical difference in Ozempic and Wegovy for patients choosing between them. Questions that do not fit neatly into a page are best taken to our FAQs or directly to the team via the contact page. Which medicine suits you is a clinical decision our prescribers make with you.